Inhibrx Biosciences Inc.(INBX)

Biotechnology · La Jolla, CA

$95.15+0.59 (+0.62%)

Delayed quote: Oct 6, 2026, 10:10 AM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T14:12:23.377Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:12:23.377Z.

Quote observation: 2026-10-06T14:10:14.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,395,963,348
Total debt · period ending 2026-06-30: 5,341,000
Cash · period ending 2026-06-30: 133,344,000
TTM operating income · period ending 2026-06-30: -127,811,000

FMP input reference: 771dc6670e9772695969b0bf6104b917a4d7f40f340cdb77ec2424dd20cacd43

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

INBX EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

INBX Competitors' EV/EBIT Ratio

INBX

Inhibrx Biosciences Inc.

Current

Market Cap

$1.40B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ANAB

AnaptysBio, Inc.

vs INBX

Market Cap

$1.43B

EV/EBIT Ratio

11.67x

TTM Avg

36.76x

3Y Avg

36.76x

5Y Avg

36.50x

KLRA

Kailera Therapeutics, Inc.

vs INBX

Market Cap

$1.35B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COAG

Hemab Therapeutics Holdings, Inc. Common Stock

vs INBX

Market Cap

$1.34B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MAZE

Maze Therapeutics, Inc.

vs INBX

Market Cap

$1.45B

EV/EBIT Ratio

N/A

TTM Avg

5.99x

3Y Avg

5.99x

5Y Avg

5.99x

BRVE

Braveheart Bio, Inc.

vs INBX

Market Cap

$1.46B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HCSG

Healthcare Services Group, Inc.

vs INBX

Market Cap

$1.47B

EV/EBIT Ratio

10.09x

TTM Avg

25.95x

3Y Avg

23.59x

5Y Avg

24.10x

AVBP

ArriVent BioPharma, Inc.

vs INBX

Market Cap

$1.33B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DRTS

Alpha Tau Medical Ltd

vs INBX

Market Cap

$1.32B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GHRS

GH Research PLC

vs INBX

Market Cap

$1.49B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Inhibrx Biosciences Inc. (INBX)	$1.40B	N/A	N/A	N/A	N/A
AnaptysBio, Inc. (ANAB)vs ›	$1.43B	11.67x	36.76x	36.76x	36.50x
Kailera Therapeutics, Inc. (KLRA)vs ›	$1.35B	N/A	N/A	N/A	N/A
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›	$1.34B	N/A	N/A	N/A	N/A
Maze Therapeutics, Inc. (MAZE)vs ›	$1.45B	N/A	5.99x	5.99x	5.99x
Braveheart Bio, Inc. (BRVE)vs ›	$1.46B	N/A	N/A	N/A	N/A
Healthcare Services Group, Inc. (HCSG)vs ›	$1.47B	10.09x	25.95x	23.59x	24.10x
ArriVent BioPharma, Inc. (AVBP)vs ›	$1.33B	N/A	N/A	N/A	N/A
Alpha Tau Medical Ltd (DRTS)vs ›	$1.32B	N/A	N/A	N/A	N/A
GH Research PLC (GHRS)vs ›	$1.49B	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

INBX EV/EBIT Ratio Metrics

INBX Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics